Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 26-May 2015. Module: Canada Health Infoway English module (core metadata concept)
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 137891000087116 | Tripacel Hybrid suspension for injection Sanofi Pasteur Limited (real clinical drug) | en | Fully specified name | Active | Entire term case sensitive (core metadata concept) | Canada Health Infoway English module (core metadata concept) |
| 23051000087115 | DTaP Tripacel Hybrid SP | en | Synonym (core metadata concept) | Active | Entire term case sensitive (core metadata concept) | Canada Health Infoway English module (core metadata concept) |
| 23071000087114 | Tripacel Hybrid suspension for injection Sanofi Pasteur Limited | en | Synonym (core metadata concept) | Active | Entire term case sensitive (core metadata concept) | Canada Health Infoway English module (core metadata concept) |
| 77421000087113 | DCaT Tripacel Hybrid SP | fr | Synonym (core metadata concept) | Active | Entire term case sensitive (core metadata concept) | Canada Health Infoway French module (core metadata concept) |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Tripacel Hybrid suspension for injection Sanofi Pasteur Limited (real clinical drug) | est un(e) (attribut) | Pediatric vaccine product containing only diphtheria standard dose + tetanus + acellular pertussis standard dose antigens (medicinal product) | true | Inferred relationship | Some | ||
| Tripacel Hybrid suspension for injection Sanofi Pasteur Limited (real clinical drug) | a pour principe actif (attribut) | Antigen of acellular Bordetella pertussis (substance) | true | Inferred relationship | Some | 2 | |
| Tripacel Hybrid suspension for injection Sanofi Pasteur Limited (real clinical drug) | Count of base of active ingredient | trois | false | Inferred relationship | Some | ||
| Tripacel Hybrid suspension for injection Sanofi Pasteur Limited (real clinical drug) | Has product characteristic | enfance | false | Inferred relationship | Some | ||
| Tripacel Hybrid suspension for injection Sanofi Pasteur Limited (real clinical drug) | est un(e) (attribut) | Corynebacterium diphtheriae toxoid antigen-containing vaccine product | true | Inferred relationship | Some | ||
| Tripacel Hybrid suspension for injection Sanofi Pasteur Limited (real clinical drug) | est un(e) (attribut) | Product manufactured as parenteral dose form (product) | true | Inferred relationship | Some | ||
| Tripacel Hybrid suspension for injection Sanofi Pasteur Limited (real clinical drug) | Plays role | Active immunity stimulant role (role) | true | Inferred relationship | Some | ||
| Tripacel Hybrid suspension for injection Sanofi Pasteur Limited (real clinical drug) | Has ingredient characteristic (attribute) | dose élevée | false | Inferred relationship | Some | 1 | |
| Tripacel Hybrid suspension for injection Sanofi Pasteur Limited (real clinical drug) | Has supplier | Sanofi Pasteur Limited (supplier) | true | Inferred relationship | Some | ||
| Tripacel Hybrid suspension for injection Sanofi Pasteur Limited (real clinical drug) | Has ingredient characteristic (attribute) | dose élevée | false | Inferred relationship | Some | 2 | |
| Tripacel Hybrid suspension for injection Sanofi Pasteur Limited (real clinical drug) | est un(e) (attribut) | Vaccine product containing Clostridium tetani toxoid antigen (medicinal product) | true | Inferred relationship | Some | ||
| Tripacel Hybrid suspension for injection Sanofi Pasteur Limited (real clinical drug) | a pour principe actif (attribut) | Tetanus toxoid | true | Inferred relationship | Some | 3 | |
| Tripacel Hybrid suspension for injection Sanofi Pasteur Limited (real clinical drug) | a une forme pharmaceutique (attribut) | forme pharmaceutique pour usage parentéral (forme pharmaceutique) | true | Inferred relationship | Some | ||
| Tripacel Hybrid suspension for injection Sanofi Pasteur Limited (real clinical drug) | a pour principe actif (attribut) | Diphtheria toxoid | true | Inferred relationship | Some | 1 | |
| Tripacel Hybrid suspension for injection Sanofi Pasteur Limited (real clinical drug) | Has ingredient qualitative strength | Standard dose (qualifier value) | true | Inferred relationship | Some | 1 | |
| Tripacel Hybrid suspension for injection Sanofi Pasteur Limited (real clinical drug) | Has target population | Pediatric population (qualifier value) | true | Inferred relationship | Some | ||
| Tripacel Hybrid suspension for injection Sanofi Pasteur Limited (real clinical drug) | Has ingredient qualitative strength | Standard dose (qualifier value) | true | Inferred relationship | Some | 2 | |
| Tripacel Hybrid suspension for injection Sanofi Pasteur Limited (real clinical drug) | a pour principe actif (attribut) | Pertussis vaccine (substance) | false | Inferred relationship | Some | 1 | |
| Tripacel Hybrid suspension for injection Sanofi Pasteur Limited (real clinical drug) | a pour principe actif (attribut) | Vaccin tétanos | false | Inferred relationship | Some | 2 | |
| Tripacel Hybrid suspension for injection Sanofi Pasteur Limited (real clinical drug) | a pour principe actif (attribut) | Diphtheria vaccine (substance) | false | Inferred relationship | Some | 3 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Reference Sets
Administered tradename codes for vaccines reference set (foundation metadata concept)
FHIR